Editorial: accelerated infliximab induction-it's time to settle the debate! Authors' reply

Aliment Pharmacol Ther. 2019 Nov;50(9):1061-1062. doi: 10.1111/apt.15498.

Authors

Shaji Sebastian¹, Nicholas A Kennedy², Sreedhar Subramanian³, Tim Raine⁴

Affiliations

¹ IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK.
² Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
³ Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
⁴ Addenbrooke's Hospital, Cambridge, UK.

PMID: 31625193
DOI: 10.1111/apt.15498

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal*
Colitis*
Humans
Infliximab
Propensity Score
Retrospective Studies

Substances

Antibodies, Monoclonal
Infliximab